Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
2(22%)
Results Posted
133%(4 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
4
44%
Ph early_phase_1
1
11%
Ph phase_1
2
22%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
Recruiting1
unknown1
Active, not recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 12 (28.6%)
Phase 24 (57.1%)

Trials by Status

terminated222%
recruiting111%
unknown111%
completed333%
active_not_recruiting111%
enrolling_by_invitation111%

Recent Activity

2 active trials
Showing 5 of 9
unknown

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

NCT05776134
recruitingphase_2

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

NCT06553872
completedphase_2

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

NCT02601313
terminatedphase_2

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

NCT05537766
active_not_recruitingearly_phase_1

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

NCT05495464
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05776134

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Unknown
NCT06553872Phase 2

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Recruiting
NCT02601313Phase 2

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

Completed
NCT05537766Phase 2

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

Terminated
NCT05495464Early Phase 1

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Active Not Recruiting
NCT05041309

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling By Invitation
NCT04880434Phase 2

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

Completed
NCT02614066Phase 1

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Completed
NCT03624036Phase 1

Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Terminated

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9